Cue Biopharma, Inc.
Moat Score — Cue Biopharma, Inc.
Total Moat Score
1 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | Exclusive license rights to specific molecules (the Einstein-licensed Immuno-STAT IP underlying CUE-101/CUE-401, and the newly in-licensed Ascendant-221/CUE-221 patents) provide narrow, asset-specific protection, but there is no approved product, brand, or platform-wide competitive barrier. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small, serially dilutive clinical-stage biotech with recently overhauled leadership and deal-related overhead, Cue has no cost advantage versus far larger, better-resourced immunology and oncology competitors it names in its own filings (Amgen, BMS, Merck). |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no commercial products, Cue has zero current pricing power; any future pricing power for CUE-221 or CUE-401 depends entirely on unproven Phase 2/Phase 1 data still pending as of Q3 2026. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effects exist in clinical-stage drug development; value does not compound with the number of patients, prescribers, or partners engaged. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product and no prescriber or patient base to retain, there are no switching costs to speak of; any future switching-cost dynamics would only emerge post-approval. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | At a ~$228 million market cap against competitors many times its size, and with a history of going-concern risk and reverse-split dilution, Cue has no scale-based barrier deterring larger, better-capitalized rivals from pursuing the same indications. |